本文選題：胰腺疾病 + 專(zhuān)利分析　； 參考：《山西醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:胰腺疾病發(fā)病率逐年增高,患病人群逐年龐大,嚴(yán)重威脅公眾健康。通過(guò)對(duì)其藥物專(zhuān)利信息進(jìn)行挖掘與解讀,可以了解研發(fā)動(dòng)態(tài),掌握國(guó)際競(jìng)爭(zhēng)態(tài)勢(shì),為我國(guó)藥物研發(fā)和專(zhuān)利布局提供重要參考。方法:本文主要使用了專(zhuān)利分析法,并結(jié)合藥學(xué)專(zhuān)業(yè)知識(shí),對(duì)胰腺疾病藥物專(zhuān)利國(guó)內(nèi)外申請(qǐng)態(tài)勢(shì)進(jìn)行了系統(tǒng)分析。專(zhuān)利分析法包括定性分析與定量分析,通過(guò)對(duì)專(zhuān)利申請(qǐng)量、申請(qǐng)區(qū)域、申請(qǐng)技術(shù)領(lǐng)域、申請(qǐng)學(xué)科領(lǐng)域、申請(qǐng)人、發(fā)明人等指標(biāo)的定量分析與對(duì)專(zhuān)利法律狀態(tài)指標(biāo)的定性分析。結(jié)果:1.國(guó)際該領(lǐng)域的藥物研發(fā)處于平穩(wěn)遞減時(shí)期,技術(shù)趨于成熟;化學(xué)、藥理學(xué)與藥學(xué)、工程學(xué)、計(jì)算機(jī)科學(xué)等不同學(xué)科領(lǐng)域之間正在相互滲透;美國(guó)、日本、中國(guó)及部分歐洲國(guó)家是主要申請(qǐng)區(qū)域;通用抗炎藥物與癌癥治療是主要技術(shù)領(lǐng)域;美國(guó)默克集團(tuán)、日本武田藥品工業(yè)株式會(huì)社及德國(guó)勃林格殷格翰公司作為技術(shù)引領(lǐng)者,擁有大量專(zhuān)利,領(lǐng)先優(yōu)勢(shì)明顯,近年來(lái)專(zhuān)利數(shù)量增長(zhǎng)迅速,技術(shù)研發(fā)逐步增強(qiáng);美國(guó)默克集團(tuán)、諾華公司、強(qiáng)生公司以及輝瑞公司具有較強(qiáng)的合作能力。2.國(guó)內(nèi)該領(lǐng)域的藥物研發(fā)處于快速增長(zhǎng)階段,市場(chǎng)廣闊;處于實(shí)質(zhì)審查法律狀態(tài)中的專(zhuān)利數(shù)量占到三分之一,新技術(shù)發(fā)展?jié)摿薮?山東省、江蘇省、上海市等是主要申請(qǐng)區(qū)域;傳統(tǒng)草藥的研發(fā)與利用是重點(diǎn)關(guān)注的技術(shù)領(lǐng)域;廣東東陽(yáng)光藥業(yè)有限公司以及南京大學(xué)、中國(guó)人民解放軍第二軍醫(yī)大學(xué)等高校掌握大量專(zhuān)利技術(shù),吳俊華、張英俊團(tuán)隊(duì)、卞永興等是該領(lǐng)域核心發(fā)明人。結(jié)論:1.國(guó)際專(zhuān)利申請(qǐng)數(shù)量回緩,國(guó)內(nèi)專(zhuān)利申請(qǐng)數(shù)量激增,現(xiàn)階段,相關(guān)制藥企業(yè)及研發(fā)機(jī)構(gòu)應(yīng)注重知識(shí)積累與沉淀,提升自身科研素質(zhì),充分利用現(xiàn)有知識(shí),掌握核心技術(shù),尋找潛在合作伙伴,同時(shí)盡早跑馬圈地,搶占市場(chǎng)。2.教育水平與經(jīng)濟(jì)實(shí)力影響專(zhuān)利申請(qǐng),對(duì)于科研產(chǎn)出高的地區(qū),應(yīng)鼓勵(lì)該地區(qū)制藥企業(yè)、科研單位走出去,積極尋找與美國(guó)、日本等國(guó)家的合作機(jī)會(huì),取長(zhǎng)補(bǔ)短;同時(shí),加快科技轉(zhuǎn)化,使專(zhuān)利技術(shù)更早地改善胰腺疾病患者的治療水平。3.通用抗炎藥物、一般癌癥治療及傳統(tǒng)草藥的開(kāi)發(fā)與利用是主要技術(shù)方向,在胰腺疾病治療藥物研發(fā)中起著重要的支撐作用,應(yīng)在研發(fā)投入上稍有側(cè)重,發(fā)展新技術(shù),迅速占領(lǐng)市場(chǎng),提升自身競(jìng)爭(zhēng)力與影響力。4.制藥企業(yè)以及高等院校是主要申請(qǐng)人,應(yīng)促進(jìn)合作,拓寬研究領(lǐng)域,加深研究深度,優(yōu)化專(zhuān)利布局,提高整體的專(zhuān)利水平,獲得共贏;同時(shí),在不斷的引進(jìn)和消化的過(guò)程中,還應(yīng)注意對(duì)我國(guó)自主知識(shí)產(chǎn)權(quán)的保護(hù)。
[Abstract]:Objective: the incidence of pancreatic diseases is increasing year by year and the number of people suffering from pancreatic diseases is increasing year by year, which is a serious threat to public health.By digging and interpreting the information of drug patent, we can understand the research and development trends, grasp the international competition situation, and provide an important reference for our country's drug research and development and patent layout.Methods: the patent analysis method was used in this paper, and the patent application situation at home and abroad for pancreatic diseases was systematically analyzed.Patent analysis includes qualitative analysis and quantitative analysis, through the quantitative analysis of patent application volume, application area, application technology field, application subject field, applicant, inventor and so on, and the qualitative analysis of patent legal status index.The result is 1: 1.International drug research and development in this field is in a period of steady decline, technology tends to mature; chemistry, pharmacology and pharmaceutical, engineering, computer science and other different disciplines are infiltrating each other; the United States, Japan,In recent years, the number of patents has increased rapidly, technology research and development has been gradually enhanced; Merck Group, Novartis, Johnson and Pfizer have strong cooperation ability.The domestic drug research and development in this field is in the stage of rapid growth, the market is broad, the number of patents in the legal state of substantive examination accounts for 1/3, the development potential of new technology is huge, Shandong Province, Jiangsu Province, Shanghai and so on are the main application areas;The research and development and utilization of traditional herbal medicines are the key technical fields; Guangdong Dongyang Pharmaceutical Co., Ltd., Nanjing University, the second military Medical University of the Chinese people's Liberation Army and other universities have a large number of patented technologies. Wu Junhua, Zhang Ching's team,Bian Yongxing and others are the core inventors in this field.Conclusion 1.The number of international patent applications has slowed down, and the number of domestic patent applications has increased sharply. At the present stage, relevant pharmaceutical enterprises and R & D institutions should pay attention to the accumulation and precipitation of knowledge, improve their own scientific research quality, fully utilize existing knowledge, and master core technologies.Looking for potential partners, while at the same time, as early as possible to seize the market. 2.The level of education and economic strength affect patent applications. For areas with high scientific research output, pharmaceutical enterprises and scientific research institutions in the region should be encouraged to go out and actively seek opportunities for cooperation with the United States, Japan, and other countries.Accelerate the transformation of science and technology, so that patent technology to improve the treatment of pancreatic disease patients. 3. 3.The development and utilization of general anti-inflammatory drugs, general cancer treatment and traditional herbs are the main technical directions. They play an important supporting role in the research and development of pancreatic disease treatment drugs, so we should put a little emphasis on the R & D investment and develop new technologies.Quickly occupy the market, enhance their competitiveness and influence. 4.Pharmaceutical enterprises and institutions of higher learning are the main applicants. They should promote cooperation, broaden research fields, deepen research depth, optimize patent layout, improve the overall patent level, and obtain win-win results. At the same time, in the process of continuously introducing and digesting,Attention should also be paid to the protection of independent intellectual property rights in China.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R975;G306

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 秦亞飛;;重癥急性胰腺炎早期液體復(fù)蘇對(duì)氧合指數(shù)及預(yù)后的影響[J];中國(guó)實(shí)用醫(yī)藥;2016年15期

2 杜凱;馬宏s，

本文編號(hào)：1736827